Mefloquine is active in vitro and in vivo against Mycobacterium avium complex

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 8, 1999, Pages 1870-1874

  Bermudez, Luiz E ^a   Kolonoski, Peter ^a   Wu, Martin ^a   Aralar, Priscilla A ^b   Inderlied, Clark B ^b   Young, Lowell S ^a  

^a Kuzell Institute for Arthritis and Infectious Diseases   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; MEFLOQUINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; PRIORITY JOURNAL;

EID: 0032876004     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.8.1870     Document Type: Article

References (22)

1. Bermudez, L. E., C. B. Inderlied, P. Kolonoski, M. Petrofsky, and L. S. Young. 1994. Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice. Antimicrob. Agents Chemother. 38:2717-2722.
2. Bermudez, L. E., C. B. Inderlied, P. Kolonoski, M. Wu, L. Barbara-Burnham, and L. S. Young. 1996. Activity of Bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice. Antimicrob. Agents Chemother. 40:546-551.
3. Bermudez, L. E., M. Petrofsky, P. Kolonoski, and L. S. Young. 1998. Emergence of Mycabacterium avium populations resistant to macrolides during experimental chemotherapy. Antimicrob. Agents Chemother. 42:180-183.
4. Bermudez, L. E., and L. S. Young. 1995. New drugs for the therapy of mycobacterial infections. Curr. Opin. Infect. Dis. 8:428-437.
5. Bermudez, L. E., and L. S. Young. 1988. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing ni Mycobacterium avium complex. J. Immunol. 9:3006-3013.
6. Chaisson, R. E., C. A. Season, M. P. Dube, L. B. Heifets, J. A. Korvick, S. Elkin, T. Smith, J. C. Craft, F. R. Sattler, and the AIDS Clinical Trials Group Protocol 157 Study Team. 1994. Clarithromycin therapy for bacteremic Mycobacterium avium complex. Ann. Intern. Med. 121:905-911.
7. Croft, A. M., T. C. Clayton, and M. J. World. 1997. Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial. Trans. R. Soc. Trop. Med. Hyg. 91:199-203.
8. Desneves, J., G. Thorn, A. Berman, D. Galatis, N. LaGreca, J. Sinding, M. Foley, L. W. Deady, A. F. Cownian, and L. Tilley. 1996. Photoaffinity labeling of mefloquine-binding proteins in human serum, uninfected erythrocytes and Plasmodium falciparum-infected erythrocytes. Mol. Biochem. Parasitol. 82: 182-194.
9. Falkinham, J. O., III. 1996. Epidemiology of infection by nontuberculous mycobacteria. Clin. Microbiol. Rev. 9:177-215.
10. Foley, M., and L. Tilley. 1998. Quinolone antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol. Ther. 79: 55-87.
11. Gilman, A. G., et al. (ed.). 1993. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. McGraw-Hill, New York, N. Y.
12. Havlir, D. V., M. P. Dube, F. R. Sattler, D. N. Fortal, C. A. Demper, M. W. Dunne, D. M. Parenti, J. P. Lavelle, A. C. White, Jr., M. D. Witt, S. A. Bozzette, J. A. McCutchan, and the California Collaborative Treatment Group. 1996. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N. Engl. J. Med. 335:392-398.
13. Horsburgh, C. R., Jr. 1991. Mycobacterium avium complex in the acquired immunodeficiency syndrome (AIDS). N. Engl. J. Med. 324:1332-1338.
14. Inderlied, C. B., C. A. Kemper, and L. E. M. Bermudez. 1993. The Mycobacterium avium complex. Clin. Microbiol. Rev. 6:266-310.
15. Inderlied, C. B., L. S. Young, and J. K. Yamada. 1987. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob. Agents Chemother. 31:1697-1702.
16. Karbwang, J., D. Bunnag, A. M. Breckenridge, and D. J. Back. 1987. The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects. Eur. J. Clin. Pharmacol. 32:173-177.
17. Korvick, J., and C. Benson. 1996. Advances in the treatment and prophylaxis of Mycobacterium avium complex in individuals infected with human immunodeficiency virus, p. 241-262. In J. Korvick and C. Benson (ed.), Mycobacterium avium-complex infection: progress in research and treatment. Marcel Dekker, Inc., New York, N.Y.
18. Schlesinger, P. H., D. J. Krogstad, and B. L. Herwaldt. 1988. Antimicrobial agents: mechanisms of action. Antimicrob. Agents Chemother. 32:793-798.
19. Schmidt, L. H., R. Crosby, J. Rasco, and D. Vaughan. 1978. Antimalarial activities of various 4-quinolinemethanols with special attention to WR-142,490 (rnefloquine). Antimicrob. Agents Chemother. 13:1011-1030.
20. Sturgill-Koszycki, S., P. H. Schlesinger, P. Chakraborty, P. L. Haddix, H. L. Collins, A. K. Fok, R. D. Allen, S. L. Gluck, J. Heuser, and D. G. Russell. 1994. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 263:678-681.
21. Sullam, P. M., F. M. Gordin, B. A. Wynne, and The Rifabutin Treatment Group. 1994. Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. Clin. Infect. Dis. 19:84-86.
22. World Health Organization. 1984. Report of the Steering Committee of the Scientific Working Groups on Malaria, World Health Organization, Geneva, Switzerland.